Maia Biotechnology, INC Form 4 insider transactions

Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Louie Ngar Yee reports acquisition of stock options in MAIA Biotechnology, Inc.

Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., reported the acquisition of stock options on October 1, 2024.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Ramiro Guerrero reports acquisition of 5,728 stock options in MAIA Biotechnology, Inc.

Director Steven M. Chaouki acquired 5,728 stock options in MAIA Biotechnology, Inc. on June 30, 2024.

Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Louie Ngar Yee reports the acquisition of stock options in MAIA Biotechnology, Inc.

Director Jean-Manasse Theagene acquired 5,728 stock options in MAIA Biotechnology, Inc. on June 30, 2024.

Chief Scientific Officer Sergei Gryaznov reports the acquisition of stock options in MAIA Biotechnology, Inc.

Jeffrey Himmelreich, Head of Finance at MAIA Biotechnology, Inc., reports the acquisition of stock options.

Vlad Vitoc, CEO of MAIA Biotechnology, reports the acquisition of 200,000 stock options.

Director Louie Ngar Yee purchased 19,665 shares of common stock and warrants of MAIA Biotechnology, Inc. on April 25, 2024.

Director Stan Smith reports the acquisition of MAIA Biotechnology shares and warrants through a recent transaction.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology through a grant under the company's 2021 Equity Incentive Plan.

Director Louie Ngar Yee reports the acquisition of 13,790 stock options in MAIA Biotechnology, Inc. on March 31, 2024.

Director Steven M. Chaouki acquired 9,193 stock options in MAIA Biotechnology, Inc. on March 31, 2024.

Director Ramiro Guerrero acquired 9,193 stock options in MAIA Biotechnology, Inc. on March 31, 2024.

Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.

Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., acquired 9,193 stock options on March 31, 2024.

Director Steven M. Chaouki reports purchasing 34,641 shares of MAIA Biotechnology at $1.17 and warrants exercisable at $1.30.

Director Stan Smith purchased 170,940 shares of MAIA Biotechnology and corresponding warrants at $1.17 and $1.30 respectively, increasing his indirect holdings.

Director Louie Ngar Yee purchased 170,940 shares of MAIA Biotechnology at $1.17 per share and warrants exercisable at $1.30, increasing his direct holdings.

Cristian Luput, a director at MAIA Biotechnology, recently purchased shares and warrants of the company, increasing his holdings.

Director Ramiro Guerrero purchased 6,928 shares of MAIA Biotechnology and warrants to acquire an additional 6,928 shares on March 14, 2024.